1
|
Inanc N, Abacar KY, Ozturk MA, Tufan A, Karadeniz H, Sari I, Can G, Erez Y, Pehlivan Y, Dalkilic HE, Ocak T, Cefle A, Yazici A, Senel AS, Akar S, Durak-Ediboğlu E, Koca SS, Piskin-Sagir R, Yilmaz S, Gulcemal S, Soysal-Gunduz O, Basibuyuk CS, Alkan S, Cesur TY, Onen F. Unintentional Monotherapy in Rheumatoid Arthritis Patients Receiving Tofacitinib and Drug Survival Rate of Tofacitinib. J Clin Rheumatol 2023; 29:365-369. [PMID: 37724891 PMCID: PMC10662607 DOI: 10.1097/rhu.0000000000002026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/21/2023]
Abstract
OBJECTIVE To determine the rate of unintentional monotherapy (UM; switching to monotherapy from combination therapy of patients' own volition) in rheumatoid arthritis patients receiving tofacitinib and to evaluate tofacitinib survival rate. METHODS This national, multicenter study included patients' data from the TURKBIO Registry. Demographics, clinical characteristics, disease duration and activity, comorbidities, and treatments were analyzed. RESULTS Data of 231 rheumatoid arthritis patients (84.8% female, median age, 56 years) were included; 153 were initially prescribed combination therapy and continued to their therapies; 31 were initially prescribed combination therapy but switched to monotherapy on their own volition (UM); 21 were initially prescribed monotherapy and switched to combination therapy; 26 were initially prescribed monotherapy and continued to their therapies. The rate of comorbidities at the time of data retrieval was higher in the UM group than in the combination group (83.3% vs. 60.3%, p = 0.031). Presence of comorbidities was a significant factor affecting switching to monotherapy ( p = 0.039; odds ratio, 3.29; 95% confidence interval, 1.06-10.18). The combination and UM groups did not differ regarding remission rate assessed by Disease Activity Score 28-joint count C-reactive protein (60.5% and 70%, respectively; p = 0.328). Drug survival rates of the UM and combination groups did not differ. The median drug survival duration of tofacitinib was 27+ months with 1- and 4-year drug survival rates of 89.6% and 60.2%, respectively, in the UM group. CONCLUSIONS Although 13.4% of the study population started monotherapy unintentionally, drug survival and remission rates of the UM and combination groups were not different. Comorbidity was a factor affecting transition from combination therapy to monotherapy.
Collapse
Affiliation(s)
- Nevsun Inanc
- From the Division of Rheumatology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul
| | - Kerem Y. Abacar
- From the Division of Rheumatology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul
| | - Mehmet A. Ozturk
- Division of Rheumatology, Department of Internal Medicine, Gazi University School of Medicine, Ankara
| | - Abdurrahman Tufan
- Division of Rheumatology, Department of Internal Medicine, Gazi University School of Medicine, Ankara
| | - Hazan Karadeniz
- Division of Rheumatology, Department of Internal Medicine, Gazi University School of Medicine, Ankara
| | - Ismail Sari
- Division of Rheumatology, Department of Internal Medicine, Dokuz Eylül University Hospital, İzmir
| | - Gercek Can
- Division of Rheumatology, Department of Internal Medicine, Dokuz Eylül University Hospital, İzmir
| | - Yesim Erez
- Division of Rheumatology, Department of Internal Medicine, Dokuz Eylül University Hospital, İzmir
| | - Yavuz Pehlivan
- Division of Rheumatology, Department of Internal Medicine, Bursa Uludag University School of Medicine, Bursa
| | - Huseyin E. Dalkilic
- Division of Rheumatology, Department of Internal Medicine, Bursa Uludag University School of Medicine, Bursa
| | - Tugba Ocak
- Division of Rheumatology, Department of Internal Medicine, Bursa Uludag University School of Medicine, Bursa
| | - Ayse Cefle
- Division of Rheumatology, Kocaeli University School of Medicine, Kocaeli
| | - Ayten Yazici
- Division of Rheumatology, Kocaeli University School of Medicine, Kocaeli
| | | | - Servet Akar
- Division of Rheumatology, Department of Internal Medicine, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir
| | - Elif Durak-Ediboğlu
- Division of Rheumatology, Department of Internal Medicine, Izmir Katip Celebi University Ataturk Training and Research Hospital, Izmir
| | - Suleyman S. Koca
- Division of Rheumatology, Department of Internal Medicine, Firat University School of Medicine, Elazıg
| | - Rabia Piskin-Sagir
- Division of Rheumatology, Department of Internal Medicine, Firat University School of Medicine, Elazıg
| | - Sema Yilmaz
- Division of Rheumatology, Department of Internal Medicine, Selcuk University School of Medicine, Konya
| | - Semral Gulcemal
- Division of Rheumatology, Department of Internal Medicine, Selcuk University School of Medicine, Konya
| | - Ozgul Soysal-Gunduz
- Division of Rheumatology, Department of Internal Medicine, Manisa Celal Bayar University Hafsa Sultan Hospital, Manisa
| | | | - Serdar Alkan
- Inflammation and Immunology, Pfizer Pharmaceuticals, Istanbul, Turkey
| | - Teoman Y. Cesur
- Inflammation and Immunology, Pfizer Pharmaceuticals, Istanbul, Turkey
| | - Fatos Onen
- Division of Rheumatology, Department of Internal Medicine, Dokuz Eylül University Hospital, İzmir
| |
Collapse
|
2
|
Direskeneli H, Karadag O, Ates A, Tufan A, Inanc N, Koca SS, Cetin GY, Akar S, Cinar M, Yilmaz S, Yilmaz N, Dalkilic E, Bes C, Yilmazer B, Sahin A, Ersözlü D, Tezcan ME, Sen N, Keser G, Kalyoncu U, Armagan B, Hacibedel B, Helvacioglu K, Cesur TY, Basibuyuk CS, Alkan S, Gunay LM. Quality of life, disease activity and preferences for administration routes in rheumatoid arthritis: a multicentre, prospective, observational study. Rheumatol Adv Pract 2022; 6:rkac071. [PMID: 36133962 PMCID: PMC9486987 DOI: 10.1093/rap/rkac071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2021] [Accepted: 07/10/2022] [Indexed: 11/22/2022] Open
Abstract
Objective We aimed to evaluate quality of life (QoL), disease activity, compliance to treatment, patient and physician preferences for route of administration (RoA), status of health and pain in RA patients starting advanced treatments or needing a switch, and the factors associated with patient preferences. Methods A multicentre, prospective, observational and 1-year follow-up study was conducted, between 2015 and 2020, in adult RA patients using advanced treatments for the first time or needing a switch in their current treatments. All the data collected were entered into electronic case report forms. DAS in 28 joints with ESR [DAS28-4(ESR)], EuroQol 5-Dimensional Questionnaire (EQ-5D), HAQ Disability Index (HAQ-DI), Compliance Questionnaire for Rheumatology (CQR-19), Work Productivity and Activity Impairment Instrument (WPAI) and Patient Global Assessment-Visual Analogue Scale (PGA-VAS) questionnaires were used for longitudinal assessments. Results Four hundred and fifty-nine patients were enrolled. Three hundred and eight patients (67.1%) attended the final study visit at 12 months and were included for comparative analyses. Irrespective of RoA, the disease activity and QoL improved significantly at 12 months, whereas compliance worsened. At baseline and 12 months, EQ-5D and DAS28-4(ESR) scores were significantly correlated (P < 0.001). The WPAI scores changed significantly in favour of better outcomes over 12 months after initiation of advanced treatment or switching (P < 0.001). A higher proportion of patients preferred an oral RoA, in comparison to physicians (53.6% vs 31.4%; P < 0.001). Patient and physician RoA preferences were independent of gender, age, disease duration, advanced treatment type and the EQ-5D-3L, DAS28-4(ESR), HAQ-DI, PGA-VAS and CQR-19 scores at baseline. Conclusion The oral route was more frequently preferred by patients compared with physicians, although patients’ preference rates showed a slight increase towards the end of the treatment, which might be an important factor for RA outcomes. Better control of disease activity and QoL were achieved at 12 months, regardless of RoA.
Collapse
Affiliation(s)
- Haner Direskeneli
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Marmara University , Istanbul, Turkey
| | - Omer Karadag
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University , Ankara, Turkey
| | - Askin Ates
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara University , Ankara, Turkey
| | - Abdurrahman Tufan
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Gazi University , Ankara, Turkey
| | - Nevsun Inanc
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Marmara University , Istanbul, Turkey
| | - Serdar S Koca
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Fırat University , Elazıg, Turkey
| | - Gozde Y Cetin
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Kahramanmaras Sutcu Imam University , Kahramanmaras, Turkey
| | - Servet Akar
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Izmir Katip Celebi University , Izmir, Turkey
| | - Muhammet Cinar
- Clinic of Rheumatology, Gulhane Faculty of Medicine, Gulhane Training and Research Hospital, Health Science University , Ankara, Turkey
| | - Sedat Yilmaz
- Clinic of Rheumatology, Gulhane Faculty of Medicine, Gulhane Training and Research Hospital, Health Science University , Ankara, Turkey
| | - Neslihan Yilmaz
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, TC Demiroglu Bilim University , Istanbul, Turkey
| | - Ediz Dalkilic
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Uludag University , Bursa, Turkey
| | - Cemal Bes
- Clinic of Rheumatology, Department of Internal Medicine, Istanbul Provincial Health Directorate, Basaksehir Cam and Sakura City Hospital , Istanbul, Turkey
| | - Baris Yilmazer
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Trakya University , Edirne, Turkey
| | - Ali Sahin
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Cumhuriyet University , Sivas, Turkey
| | - Duygu Ersözlü
- Clinic of Rheumatology, Department of Internal Medicine, SBU Adana City Training and Research Hospital , Adana, Turkey
| | - Mehmet E Tezcan
- Division of Rheumatology, Department of Internal Medicine, Istanbul Provincial Health Directorate, Istanbul Kartal Dr. Lutfi Kırdar Training and Research Hospital , Istanbul, Turkey
| | - Nesrin Sen
- Division of Rheumatology, Department of Internal Medicine, Istanbul Provincial Health Directorate, Istanbul Kartal Dr. Lutfi Kırdar Training and Research Hospital , Istanbul, Turkey
| | - Gokhan Keser
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ege University , Izmir, Turkey
| | - Umut Kalyoncu
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University , Ankara, Turkey
| | - Berkan Armagan
- Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University , Ankara, Turkey
| | | | | | | | | | | | | |
Collapse
|